Loss of tyrosine 211 phosphorylation of proliferating cell nuclear antigen (PCNA) enhances postnatal mammary gland development.

Mammary gland PCNA Phosphorylation

Journal

BioMedicine
ISSN: 2211-8020
Titre abrégé: Biomedicine (Taipei)
Pays: China (Republic : 1949- )
ID NLM: 101611451

Informations de publication

Date de publication:
2024
Historique:
received: 07 03 2024
accepted: 02 05 2024
medline: 10 10 2024
pubmed: 10 10 2024
entrez: 10 10 2024
Statut: epublish

Résumé

The intricately orchestrated progression of mammary tissue development involves the precise coordination of gland differentiation and cellular proliferation. Nevertheless, the understanding of the role and regulatory mechanisms governing the DNA replication machinery in mammary gland development remains limited. Given the essential role of DNA replication in the viability of living cells, any genetic disturbance to its replicative function, in any form, will impede organ development. This circumstance poses a technical challenge in elucidating the potential function of cell proliferation in mammary morphogenesis. PCNA is crucial in DNA replication, playing a pivotal role in the development of complete eukaryotic organisms. The phosphorylation of PCNA at tyrosine 211 (Y211) has been demonstrated to play a significant role in supporting replication forks and, consequently, cell proliferation. Therefore, the utilization of a knock-in mouse model, wherein the Y211 residue of PCNA is replaced with phenylalanine (211F), presents an opportunity to evaluate the impact of reduced cell proliferation potential on mammary gland development. Interestingly, the lack of Y211 phosphorylation did not significantly impact the rates of proliferation or cell death in the mammary gland. In contrast, the absence of Y211PCNA led to an increased, rather than reduced, growth of the mammary gland. This was evident in assessments of gland length and the number of terminal end buds (TEBs) in both postnatal and virgin mammary glands. Notably, this observation correlated with an elevation in tissue stemness within the 211F glands compared to the WT glands. Additionally, it was consistent with the greater body weight gains observed in 211F pups compared to WT pups during the weaning period. Our findings unveil an unexpected aspect that may carry significance for mammary development. This newfound is associated with the regulation of a central component within the DNA replication machinery, providing insights into the intricate interplay governing mammary tissue expansion.

Identifiants

pubmed: 39386182
doi: 10.37796/2211-8039.1462
pii: bmed-14-03-040
pmc: PMC11460574
doi:

Types de publication

Journal Article

Langues

eng

Pagination

40-48

Informations de copyright

© the Author(s).

Déclaration de conflit d'intérêts

Conflicts of interest: The authors declare no conflict of interest.

Auteurs

Yi-Chun Shen (YC)

Center for Molecular Medicine, China Medical University Hospital, Taichung 404327, Taiwan.
Cancer Biology and Precision Therapeutics Center, China Medical University, Taichung 406040, Taiwan.

You-Zhe Lin (YZ)

Cancer Biology and Precision Therapeutics Center, China Medical University, Taichung 406040, Taiwan.

Wan-Rong Wu (WR)

Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 406040, Taiwan.

Pei-Le Lin (PL)

Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 406040, Taiwan.

Chien-Ching Liao (CC)

Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 406040, Taiwan.

Feng-Chi Chung (FC)

Cancer Biology and Drug Discovery Ph.D. Program, China Medical University, Taichung 406040, Taiwan.

Chia-Yun Chen (CY)

Department of General Medicine, China Medical University Hospital, Taichung 404327, Taiwan.
School of Medicine, China Medical University, Taichung 406040, Taiwan.

Ching-Yu Weng (CY)

Department of General Medicine Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833401, Taiwan.
School of Medicine, China Medical University, Taichung 406040, Taiwan.

Shao-Chun Wang (SC)

Center for Molecular Medicine, China Medical University Hospital, Taichung 404327, Taiwan.
Cancer Biology and Precision Therapeutics Center, China Medical University, Taichung 406040, Taiwan.
Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 406040, Taiwan.
Cancer Biology and Drug Discovery Ph.D. Program, China Medical University, Taichung 406040, Taiwan.
Department of Biotechnology, Asia University, Taichung 413305, Taiwan.
Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45267, USA.

Classifications MeSH